Recognized for its proprietary SELPAXT™ technology, Chromafora is setting a new standard for innovation and performance in advanced PFAS remediation.…
MILAN, Italy, June 06, 2025 – Italfarmaco S.p.A. announced today that the European Commission (EC) has granted conditional marketing authorisation…
June 05, 2025 16:31 ET | Source: ImPact Biotech – Previously inoperable patient converted to eligible for resection, underwent pancreaticoduodenectomy,…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)…
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal…
New global education initiative unveiled at 2025 PTCOG Annual Conference Louvain-la-Neuve, Belgium, 4 June 2025 - IBA (Ion Beam Applications…
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1…
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic…
More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of…
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED)…